We’re pleased to announce the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed acceptance of the UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer’s disease.
This application is being reviewed within the scope of the 150-day accelerated assessment procedure, which is used by MHRA to accelerate the availability of medicines for patients in the UK.
We look forward to sharing further updates as the application progresses.
